20 Lighter Fat Burner

Product NDC

70418-002

11-digit product format

704180002

Labeler code

70418

Product ID

70418-002_35526e20-6d1d-1757-e054-00144ff88e88

Type

HUMAN PRESCRIPTION DRUG

Nonproprietary name

20L-A PEPTIDES

Dosage form

LIQUID

Route

ORAL

Labeler

20Lighter Health & Wellness, LLC

Marketing category

UNAPPROVED HOMEOPATHIC

Marketing start

2016-03-04

Marketing end

0000-00-00

Substance

SEMECARPUS ANACARDIUM JUICE; .ALPHA.-LIPOIC ACID; BELLADONNA LEAF; EQUOL, (+)-; SUS SCROFA ESOPHAGUS; FORMIC ACID; SUS SCROFA GALLBLADDER; INSULIN ARGINE; SULFUR; HUMAN THYMUS; SUS SCROFA URINARY BLADDER; VERATRUM ALBUM ROOT; CYNANCHUM VINCETOXICUM ROOT; PORK LIVER; CARAPICHEA IPECACUANHA WHOLE; LYCOPODIUM CLAVATUM WHOLE; MENADIONE; METHYLCOBALAMIN; MOMORDICA BALSAMINA WHOLE; STRYCHNOS NUX-VOMICA SEED; SUS SCROFA ORAL MUCOSA; SUS SCROFA PANCREAS; PHOSPHORUS; PHYTOLACCA AMERICANA ROOT; SUS SCROFA DUODENUM; HYDRASTIS CANADENSIS WHOLE; GELSEMIUM SEMPERVIRENS ROOT; CEANOTHUS AMERICANUS LEAF; SUS SCROFA ILEUM; LACHESIS MUTA VENOM; SUS SCROFA LUNG; SUS SCROFA NASAL MUCOSA; PULSATILLA VULGARIS; LACTIC ACID, L-; ADENOSINE TRIPHOSPHATE; AVENA SATIVA FLOWERING TOP; MILK THISTLE; CHELIDONIUM MAJUS; CHOLESTEROL; GLUCAGON; SILVER NITRATE; MARSDENIA CUNDURANGO WHOLE; CYNARA SCOLYMUS LEAF; YEAST MANNAN; SUS SCROFA CEREBRUM; SHIGELLA DYSENTERIAE; ECHINACEA ANGUSTIFOLIA; SUS SCROFA EYE; SUS SCROFA HYPOTHALAMUS; PORK INTESTINE; SUS SCROFA JEJUNUM; MANDRAGORA OFFICINARUM ROOT; PROTEUS INCONSTANS; PORK KIDNEY; SUS SCROFA STOMACH; GAMBOGE; OYSTER SHELL CALCIUM CARBONATE, CRUDE; TARAXACUM OFFICINALE; WOOD CREOSOTE; SUS SCROFA BILE DUCT; GRAPHITE; GLYOXAL; CINCHONA OFFICINALIS BARK; SUS SCROFA COLON; .ALPHA.-KETOGLUTARIC ACID

Active strength

8 [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL

Pharmacologic classes

Non-Standardized Plant Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Allergens [CS],Plant Proteins [CS],Seed Storage Proteins [CS],Antihypoglycemic Agent [EPC],Gastrointestinal Motility Inhibitor [EPC],Increased Gluconeogenesis [PE],Increased Glycogenolysis [PE],Decreased GI Smooth Muscle Tone [PE],Decreased GI Motility [PE],Decreased Glycolysis [PE]

NDC exclude flag

E

Listing certified through

2017-12-31

Current FDA listing

Historical FDA.report record